Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up before the market opened on Thursday. The stock had previously closed at $19.24, but opened at $20.62. Chugai Pharmaceutical shares last traded at $19.8750, with a volume of 91,313 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CHGCY shares. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 4.0%

The firm has a market cap of $65.88 billion, a P/E ratio of 21.76 and a beta of 0.60. The company’s 50 day simple moving average is $20.96 and its 200-day simple moving average is $23.21.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. On average, sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.